Skip to content

Trial · Interventional

TerminatedPhase 3Results postedRegistry data

Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

NCTNCT03364738 (opens ClinicalTrials.gov in a new tab)Other idSHP634-404Other id2017-003067-36Other id2017
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Terminated
Phase
Phase 3
Enrollment
22 participants (actual)
Sponsor
Shire · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
4 countries

United States, Canada, Denmark, Hungary

Start
26 Sept 2018
Primary completion
14 Apr 2020
Completion
14 Apr 2020
First posted
7 Dec 2017
Last update posted
7 Oct 2022
Conditions
Hypoparathyroidism

Timeline

1 trial · 1 stopped early · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2018201920202021
  1. Ph 3

    Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism

    NCT03364738

    26 Sept 2018 to 14 Apr 2020

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study is open to adults with hypoparathyroidism who complete the SHP634-101 study (PARALLAX Study). The purpose of this study is to see if rhPTH(1-84) is safe and effective in adults with hypoparathyroidism who previously participated in the SHP634-101 study. All participants enrolled in this study will receive rhPTH(1-84) once-daily for 52 weeks via an injection. Patients who complete the SHP634-101 study will have the option to screen for this extension study.

Interventions

  • rhPTH(1-84)Biological

Arms1

  • Experimental

    rhPTH(1-84)

    Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter \[mg/dL\]). Once a participant achieves a stable ACSC (2-2.25 mmol/L \[8.0-9.0mg/dL\]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (\>) 2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg will be administered.

Primary outcomes10

Outcomes the sponsor listed as primary.

  1. Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (>=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (<=) Upper Limit of Normal (ULN) at Week 24

    Time frame · At Week 24

    Registry description

    Percentage of participants who achieved ACSC values \>= to range of 1.875 mmol/L and \<= ULN at Week 24 was reported.

  2. Percentage of Participants With Total ACSC Values >= to the Range of 7.5 mg/dL (1.875 mmol/L) and <=ULN at Week 52 (End-of-treatment [EOT])

    Time frame · At Week 52 (EOT)

    Registry description

    Percentage of participants who achieved ACSC values \>= to range of 1.875 mmol/L and \<= ULN at Week 52 (EOT) was reported.

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame · From start of study drug administration to end of study (Week 56)

    Registry description

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect, and is an important medical event. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose.

  4. Number of Participants With Clinically Significant Change in Clinical Laboratory Values

    Time frame · From start of study drug administration to end of study (Week 56)

    Registry description

    Clinical laboratory assessment included hematology, serum chemistry, urine chemistry and urinalysis. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in clinical laboratory results which were deemed clinically significant by the investigator was reported.

  5. Number of Participants With Clinically Significant Change in Vital Sign

    Time frame · From start of study drug administration to end of study (Week 56)

    Registry description

    Vital sign parameters included: temperature, pulse rate, respiration rate, systolic and diastolic blood pressure. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any changes in vital signs which were deemed clinically significant by the investigator was reported.

  6. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters

    Time frame · From start of study drug administration to end of study (Week 56)

    Registry description

    Twelve-lead ECGs was performed in triplicate with a minimum 2-minute gap between traces. The participant rested in the supine position for at least 5 minutes before collecting the ECG. Assessment of ECG parameters included: heart rate, RR interval, PR interval, QRS interval, QT interval, and QTc interval. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. Any change in ECG assessments which were deemed clinically significant by the investigator was reported.

  7. Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values

    Time frame · From start of study drug administration to end of study (Week 56)

    Registry description

    eGFR was calculated using the chronic kidney disease epidemiology (CDK-epi) formula. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in eGFR assessments which were deemed clinically significant by the investigator was reported.

  8. Number of Participants With Clinically Significant Change in Serum Creatinine Value

    Time frame · From start of study drug administration to end of study (Week 56)

    Registry description

    eGFR was assessed by measuring serum creatinine. Serum creatinine level was obtained directly from laboratory results. Clinical significance was judged by the investigator based upon the out of range values of standard range set for parameter. Any change in serum creatinine assessments which were deemed clinically significant by the investigator was reported.

  9. Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 24

    Time frame · Week 24

    Registry description

    Number of participants with positive anti-parathyroid hormone antibodies at Week 24 was reported.

  10. Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 52 (EOT)

    Time frame · Week 52 (EOT)

    Registry description

    Number of participants with positive anti-parathyroid hormone antibodies at Week 52 (EOT) was reported.

Secondary outcomes(11)

  1. Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT)

    Time frame · Baseline, Weeks 24 and 52 (EOT)

    Registry description

    Change from baseline in ACSC concentration at Weeks 24 and 52 (EOT) was reported.

  2. Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

    Time frame · Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

    Registry description

    Change from baseline in serum phosphate concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported.

  3. Change From Baseline in ACSC-phosphate Product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

    Time frame · Baseline, Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT)

    Registry description

    Change from baseline in ACSC-phosphate product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) was reported. Here "mmol\^2/L\^2" is abbreviated as millimoles square per liter square.

  4. Change From Baseline in 24-hour Urine Calcium Excretion at Weeks 16, 32 and 52 (EOT)

    Time frame · Baseline, Weeks 16, 32 and 52 (EOT)

    Registry description

    Change from baseline in 24-hour urine calcium excretion at Weeks 16, 32 and 52 (EOT) was reported.

  5. Percentage Change From Baseline in Prescribed Supplemental Oral Calcium Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (End of Study [EOS])

    Time frame · Baseline and at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)

    Registry description

    Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.

  6. Percentage Change From Baseline in Prescribed Supplemental Active Vitamin D Dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)

    Time frame · Baseline, Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS)

    Registry description

    Percentage change from baseline in prescribed supplemental oral calcium dose at Weeks 4, 8, 16, 24, 32, 40, 52 (EOT) and 56 (EOS) were reported.

  7. Percentage Change From Baseline in Serum Bone-specific Alkaline Phosphatase at Weeks 8, 24 and 52 (EOT)

    Time frame · Baseline, Weeks 8, 24 and 52 (EOT)

    Registry description

    Percentage change from baseline in serum bone-specific alkaline phosphatase at Weeks 8, 24 and 52 (EOT) was reported.

  8. Percentage Change From Baseline in Serum Osteocalcin at Weeks 8, 24 and 52 (EOT)

    Time frame · Baseline, Weeks 8, 24 and 52 (EOT)

    Registry description

    Percentage change from baseline in serum osteocalcin at Weeks 8, 24 and 52 (EOT) was reported.

  9. Percentage Change From Baseline in Procollagen 1 N-Terminal Propeptide at Weeks 8, 24 and 52 (EOT)

    Time frame · Baseline, Weeks 8, 24 and 52 (EOT)

    Registry description

    Percentage change from baseline in procollagen 1 N-terminal propeptide at Weeks 8, 24 and 52 (EOT) was reported.

  10. Percentage Change From Baseline in Type I Collagen C-Telopeptides at Weeks 8, 24 and 52 (EOT)

    Time frame · Baseline, Weeks 8, 24 and 52 (EOT)

    Registry description

    Percentage change from baseline in type I collagen C-telopeptides at Week 8, 24 and 52 (EOT) was reported.

  11. Percentage Change From Baseline in Type I Collagen N-Telopeptides at Weeks 8, 24 and 52 (EOT)

    Time frame · Baseline, Weeks 8, 24 and 52 (EOT)

    Registry description

    Percentage change from baseline in type I collagen N-telopeptides at Week 8, 24 and 52 (EOT) was reported.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeNumber· At Week 24

Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (>=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (<=) Upper Limit of Normal (ULN) at Week 24

GroupValue (percentage of participants)
rhPTH(1-84)100
Primary outcomeNumber· At Week 52 (EOT)

Percentage of Participants With Total ACSC Values >= to the Range of 7.5 mg/dL (1.875 mmol/L) and <=ULN at Week 52 (End-of-treatment [EOT])

GroupValue (percentage of participants)
rhPTH(1-84)95.5
Primary outcomeCount of participants· From start of study drug administration to end of study (Week 56)

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

GroupValue (Participants)
rhPTH(1-84)17
Primary outcomeCount of participants· From start of study drug administration to end of study (Week 56)

Number of Participants With Clinically Significant Change in Clinical Laboratory Values

GroupValue (Participants)
rhPTH(1-84)0
Primary outcomeCount of participants· From start of study drug administration to end of study (Week 56)

Number of Participants With Clinically Significant Change in Vital Sign

GroupValue (Participants)
rhPTH(1-84)0
Primary outcomeCount of participants· From start of study drug administration to end of study (Week 56)

Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters

GroupValue (Participants)
rhPTH(1-84)0
Primary outcomeCount of participants· From start of study drug administration to end of study (Week 56)

Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values

GroupValue (Participants)
rhPTH(1-84)0
Primary outcomeCount of participants· From start of study drug administration to end of study (Week 56)

Number of Participants With Clinically Significant Change in Serum Creatinine Value

GroupValue (Participants)
rhPTH(1-84)0

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
rhPTH(1-84)Participants received rhPTH(1-84) (Natpara) 50 mcg, injection, subcutaneously, once daily in the thigh (alternate thigh every day) up to 52 weeks (EOT/ET). Dose escalation was done up to 100 mcg in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining ACSC levels in the range of 2-2.25 mmol/L (8-9 mg/dL). Administered dose was maintained once a participant achieved a stable ACSC level of 2-2.25 mmol/L (8-9 mg/dL) and had minimized supplement (active vitamin D and calcium supplement) doses. If ACSC was \>2.25 mmol/L (\>9.0 mg/dL), a starting dose of 25 mcg was administered.0 / 224 / 2210 / 22

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

More studies

1 study on this page

Indexing hint: Clinical trial · 2024

Corrected

Open-label extension of a randomized trial investigating safety and efficacy of rhPTH(1-84) in hypoparathyroidism.

Khan et al. 2024JBMR pluscited by 3

PMID 38741607PMC11090130DOI 10.1093/jbmrpl/ziad010PUB-38741607

CC BY
Download PDFRead the notice

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * An understanding, ability, and willingness to fully comply with study procedures and restrictions * Ability to voluntarily provide written, signed, and dated informed consent to participate in the study. * Previously completed the SHP634-101 (NCT02781844) study, including the 30-day follow-up. * Male or non-pregnant, non-lactating female subjects who agree to comply with applicable contraceptive requirements of the protocol or females of non-childbearing potential. Exclusion Criteria: * Received investigational study drug, aside from that received in study SHP634-101 (NCT02781844), within 3 months prior to the screening visit. * Presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine (with exception of the condition under study), or neurologic system(s) or psychiatric disease, that in the opinion of the investigator, would make the subject unsuitable for this study. * Received parathyroid hormone (PTH), PTH analog, or parathyroid hormone fragment 1-34 \[PTH(1-34)\] treatment within the last 30 days from the screening visit. * Subjects with a history of parathyroid hormone intolerance, based on investigator determination. * Any disease that might affect calcium metabolism or calcium-phosphate homeostasis as determined by the investigator other than hypoparathyroidism, including but not limited to, active hyperthyroidism; poorly controlled insulin-dependent diabetes mellitus or type 2 diabetes mellitus; severe and chronic cardiac, liver or renal disease; Cushing's syndrome; neuromuscular disease such as rheumatoid arthritis; myeloma; pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy, bone metastases or a history of skeletal malignancies; primary or secondary hyperparathyroidism; a history of parathyroid carcinoma; hypopituitarism, acromegaly; or multiple endocrine neoplasia types 1 and 2 . * Subjects who are at increased baseline risk for osteosarcoma such as subjects with Paget's disease of bone or unexplained elevations of alkaline phosphatase, young adult subjects with open epiphyses, subjects with hereditary disorders predisposing to osteosarcoma or subjects with a prior history of external beam or implant radiation therapy involving the skeleton. * Use of the following medications prior to administration of investigational product within: 1. 30 days-loop diuretics, lithium, systemic corticosteroids (medical judgment is required by the investigator. Primarily high doses of systemic corticosteroids \[example (eg), prednisone\] should be excluded. Stable doses of hydrocortisone \[eg, as treatment for Addison's disease\] may be acceptable). 2. 3 months-cinacalcet hydrochloride 3. 6 months-fluoride tablets, oral bisphosphonates, methotrexate, growth hormone, digoxin 4. 12 months-intravenous bisphosphonates, drug or alcohol abuse, as determined by the investigator * Presence of any clinically significant results from laboratory tests, vital signs assessments, or electrocardiograms (ECG), that in the opinion of the investigator, would make the subject unsuitable for this study. * Any medical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for this study. * History of a clinically significant illness during the 4 weeks prior to dosing, that in the opinion of the investigator, would make the subject unsuitable for this study. * History of any clinically significant surgery or procedure within 8 weeks of first dose, as determined by the investigator or expected to undergo a major surgical procedure during the trial. * History of an allergic response(s) to PTH, PTH analogs, or PTH(1-34), or other clinically significant allergies, that in the opinion of the investigator, would make the subject unsuitable for this study.

PepBank is a research reference. Talk to a doctor before you use any peptide.